Related Experiment Videos
Interstitial lung disease with pleural effusion caused by simvastin
R E De Groot1, L N Willems, J H Dijkman
1Department of Pulmonology, Leiden University Hospital, The Netherlands.
Journal of Internal Medicine
|April 1, 1996
Summary
Simvastatin, a cholesterol-lowering drug, is generally safe. However, this report details a rare case of interstitial lung disease and pleural effusion potentially linked to Simvastatin use.
Area of Science:
- Pharmacology
- Pulmonology
- Cardiology
Background:
- Simvastatin is a hydroxymethylglutaryl-Co-enzym-A (HMG-CoA) reductase inhibitor used to treat hypercholesterolemia.
- It lowers low-density lipoprotein (LDL) cholesterol by increasing hepatic LDL-receptor expression.
- Simvastatin also reduces very-low-density lipoprotein (VLDL) and increases high-density lipoprotein (HDL) cholesterol.
Observation:
- A patient developed interstitial lung disease (ILD) and pleural effusion.
- The patient's condition emerged during Simvastatin therapy.
- Causality was suspected due to the temporal relationship and known adverse effects of statins.
Findings:
- The patient presented with symptoms indicative of ILD and pleural effusion.
- Diagnostic workup suggested a link between the onset of symptoms and Simvastatin administration.
- This case highlights a potential, albeit rare, adverse pulmonary reaction to Simvastatin.
Implications:
- Clinicians should consider ILD as a potential adverse effect of Simvastatin.
- Early recognition and discontinuation of Simvastatin may be crucial for managing this complication.
- Further investigation into the mechanisms of statin-induced pulmonary toxicity is warranted.